Digital cardiac biomarkers accurately detect abnormal heart function via smartphone.
Finnish health technology company CardioSignal has successfully secured $10 million in Series A funding, supporting its mission to advance the field of heart disease detection. The funding round, which brings the total raised by the company to $23 million, was led by DigiTx Partners, with participation from Sandwater and existing investor Maki.vc.
Founded in 2017, CardioSignal specializes in digital cardiac biomarkers for the early detection of heart diseases. Its gyrocardiography technology uses the gyroscopic and accelerometer capabilities of smartphones to measure specific rotational movements of the heart. This enables accurate detection of abnormal heart function through a one-minute measurement with a smartphone placed on the patient’s chest.
Cardiovascular diseases are still the leading cause of death worldwide, and CardioSignal is seeking to leverage smartphone technology to improve health equity by enabling detection and diagnosis of patients at scale. The new funding will support additional clinical validation of the company’s technology and the expansion of its commercial efforts to scale a detection and remote monitoring solution for primary care doctors.
“More than 20 million people die each year from cardiovascular diseases,” said Dr Juuso Blomster, cardiologist and founder of CardioSignal. “Currently, primary care has very limited tools to detect heart diseases, like heart failure patients who are often already experiencing symptoms. We can support the shift in cardiovascular care from treating complications to earlier detection and prevention.”
CardioSignal’s technology, a class IIa medical device available in 15 countries, focuses on detecting atrial fibrillation and heart failure. Ongoing development includes applications for aortic stenosis, coronary artery disease, and pulmonary artery hypertension. The company currently holds 52 patents covering its gyrocardiography method and clinical algorithms.
DigiTx managing director Dr David J Kim, will join CardioSignal’s board, said that CardioSignal has the potential to meaningfully impact heart disease on a global basis.
“Besides the ability to detect various heart diseases, which continue to be one of the common causes of death, CardioSignal has lowered the barrier to the adoption of its technology by making it readily available to all individuals who have smartphones,” he added. “We can reach millions of at-risk patients and make a real impact.”